ISTH 2025 for Cardiac Surgery: LEX-211 (FARES-II) Trial Shows Promising Results
The International Society on Thrombosis and Haemostasis (ISTH) shared a post on X:
”New science from ISTH 2025! Watch this expert interview to learn about groundbreaking findings from the LEX-211 (FARES-II) trial on cardiac surgery.
Key takeaways:
- Superior efficacy
- Reduced transfusions
- Fewer serious adverse events”
To watch the full interview, follow the link.
Big news for cardiac surgery is coming from ISTH!
New data presented at ISTH 2025 from the LEX-211 (FARES-II) trial highlight significant advances in hemostatic management during cardiac surgery.
The trial demonstrated superior efficacy of LEX-211, with reduced transfusion requirements and fewer serious adverse events compared to standard care.
These findings mark a potential breakthrough in improving perioperative outcomes and patient safety in cardiac surgery.
Stay updated on the World of Thrombosis and Bleeding with Hemostasis Today.
-
Jun 4, 2026, 13:58Dietmar Dammerer: How Should We Manage Traumatic Brain Injury When on Anticoagulants?
-
Jun 4, 2026, 13:54Yaariv Khaykin: AI ECG Analysis Uncovers Hidden AF Associated With Future Stroke Risk
-
Jun 4, 2026, 13:50Gene Nudelman: Can a Hemostatic Gauze Perform When Blood Clotting is Impaired?
-
Jun 4, 2026, 13:45Edward Lee Carter: The First-Ever AHA/ACC Acute PE Guideline Is Here
-
Jun 4, 2026, 13:38Denis Oduor: The Role of Expectant Fathers in Saving Mothers and Newborns
-
Jun 4, 2026, 13:36Mohammad Reza Moghaddasnejad: Platelet Activation as a Key Driver of Breast Cancer Progression
-
Jun 4, 2026, 13:31Fredrick Chalinga: Microcytic Anemia Does Not Always Mean Iron Deficiency
-
Jun 4, 2026, 13:23How Access to Care Changed One Life – WFH
-
Jun 4, 2026, 13:16Muhammad Usman Arshad: Meta-Analysis Supports Expanding Role of DOACs in Cancer-Associated Thromboembolism